Teva said to be close to buying generic drug unit of Allergan
Petah Tikva, Israel
TEVA Pharmaceuticals is in advanced talks to buy the generic drug division of Allergan for about US$45 billion, a person briefed on the matter said on Saturday.
A deal could be announced as soon as Monday, this person said, though talks are ongoing and may still fall apart. Should an agreement be reached, it would be the latest huge deal in a wave of mergers within the healthcare space, a spree that has ranged from drugmakers to insurance providers.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales